Clinical Trials Logo

Clinical Trial Summary

The goal of the study is to understand whether blood levels of hormones produced or metabolized in the stomach reflect the health of the stomach lining. Specifically the study will determine whether the concentration of ghrelin, gastrin, pepsinogens and vitamin B12 reflect the condition of the stomach lining. Hormone concentrations for people with normal/mild gastritis will be compared to people with long-term inflammation of the stomach (chronic atrophic gastritis), and people with pre-cancerous cellular changes (intestinal metaplasia).


Clinical Trial Description

Previously published promising data show that blood levels of ghrelin, gastrin, vitamin B12 and pepsinogen are each associated with risk of developing stomach cancer. These studies used blood bank samples and looked at risk of cancer many decades later. This study was designed to explore whether these markers could be useful in a clinical setting for early detection of stomach cancer. The study will recruit at 3 sites over 1 year identifying patients with chronic atrophic gastritis and intestinal metaplasia and those with mild gastritis. Only the patient data which is absolutely necessary for analysis will be collected, to include basic demographics, relevant medical history and medications. These data will be used to analytically account for alternative explanations for variation in blood measurements of ghrelin, gastrin, pepsinogen and vitamin B12. A one-time venous blood sample will be collected to enable measurement of the markers of interest. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06085677
Study type Observational
Source Imperial College London
Contact Gwen Murphy, PhD MPH
Phone +44 20 7594 3369
Email g.murphy@imperial.ac.uk
Status Not yet recruiting
Phase
Start date November 4, 2023
Completion date September 2, 2024

See also
  Status Clinical Trial Phase
Completed NCT03313700 - Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer N/A
Recruiting NCT05645198 - The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy Phase 4
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT00144378 - Irinotecan Versus Only Best Supportive Care for Gastric Cancer Phase 3
Completed NCT00935779 - Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer N/A
Completed NCT00290966 - Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT03348150 - Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. Phase 3
Recruiting NCT02969122 - Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor N/A
Completed NCT01482299 - RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression Phase 2
Active, not recruiting NCT03760822 - Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients Phase 2
Recruiting NCT00509964 - Second-Line Irinotecan vs. ILF for AGC Phase 2
Completed NCT04889859 - Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy N/A
Completed NCT03071237 - The Origin of Infrapyloric Artery
Recruiting NCT05184803 - A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer Phase 2
Completed NCT05714878 - Multimodal Prehabilitation for Resectable Gastric Cancer N/A
Completed NCT00142038 - Docetaxel and Capecitabine in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04056260 - ICG-NIR Guided Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03065257 - Endoscopic Resection Multicenter Registry N/A
Recruiting NCT04744649 - Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial Phase 2
Recruiting NCT05640609 - Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer Phase 1/Phase 2